866-997-4948(US-Canada Toll Free)

Myocardial Fibrosis - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 65 Pages

Myocardial Fibrosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis Pipeline Review, H2 2016, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Myocardial Fibrosis Overview 7
Therapeutics Development 8
Pipeline Products for Myocardial Fibrosis - Overview 8
Pipeline Products for Myocardial Fibrosis - Comparative Analysis 9
Myocardial Fibrosis - Therapeutics under Development by Companies 10
Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes 11
Myocardial Fibrosis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Myocardial Fibrosis - Products under Development by Companies 14
Myocardial Fibrosis - Products under Investigation by Universities/Institutes 15
Myocardial Fibrosis - Companies Involved in Therapeutics Development 16
Daewoong Pharmaceutical Co Ltd 16
Evotec AG 17
Galectin Therapeutics Inc 18
GTx Inc 19
Invivosciences Inc 20
Lead Discovery Center GmbH 21
MandalMed Inc 22
miRagen Therapeutics Inc 23
Regulus Therapeutics Inc 24
Myocardial Fibrosis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Drugs for Tissue Fibrosis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
DWN-10290 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
GMCT-01 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
GRMD-02 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
GTx-878 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
MGN-4220 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NM-922 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
RG-012 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
SP-20102 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
TPI-2049 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Myocardial Fibrosis - Dormant Projects 62
Myocardial Fibrosis - Product Development Milestones 63
Featured News & Press Releases 63
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables
Number of Products under Development for Myocardial Fibrosis, H2 2016 8
Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 16
Myocardial Fibrosis - Pipeline by Evotec AG, H2 2016 17
Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2016 18
Myocardial Fibrosis - Pipeline by GTx Inc, H2 2016 19
Myocardial Fibrosis - Pipeline by Invivosciences Inc, H2 2016 20
Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H2 2016 21
Myocardial Fibrosis - Pipeline by MandalMed Inc, H2 2016 22
Myocardial Fibrosis - Pipeline by miRagen Therapeutics Inc, H2 2016 23
Myocardial Fibrosis - Pipeline by Regulus Therapeutics Inc, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Myocardial Fibrosis - Dormant Projects, H2 2016 62

List of Figures
Number of Products under Development for Myocardial Fibrosis, H2 2016 8
Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Targets, H2 2016 26
Number of Products by Stage and Targets, H2 2016 26
Number of Products by Mechanism of Actions, H2 2016 28
Number of Products by Stage and Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *